EPO906 in Carcinoid and Other Neuroendocrine Tumors
This study will examine whether the new investigational drug EPO906, given by intravenous infusion (IV directly into the vein), is effective in shrinking tumors and preventing the growth of cells that cause metastatic carcinoid and other neuroendocrine tumors.
Carcinoid|Neuroendocrine Tumors
DRUG: EPO906 epothilone B
Tumor response as assessed by radiologic techniques and/or physical examination based on Response Evaluation Criteria in Solid Tumors (RECIST), every 12 weeks
Time to progression, until documented disease progression, death or date of follow up|Overall survival, after treatment, every 3 months (maximum of 12 months)
This study will examine whether the new investigational drug EPO906, given by intravenous infusion (IV directly into the vein), is effective in shrinking tumors and preventing the growth of cells that cause metastatic carcinoid and other neuroendocrine tumors.